Accelerating antiviral drug discovery: lessons from COVID-19
During the coronavirus disease 2019 (COVID-19) pandemic, a wave of rapid and
collaborative drug discovery efforts took place in academia and industry, culminating in …
collaborative drug discovery efforts took place in academia and industry, culminating in …
On the whereabouts of SARS-CoV-2 in the human body: A systematic review
W Trypsteen, J Van Cleemput, W Snippenberg… - PLoS …, 2020 - journals.plos.org
Since SARS-CoV-2 appeared in the human population, the scientific community has
scrambled to gather as much information as possible to find good strategies for the …
scrambled to gather as much information as possible to find good strategies for the …
[HTML][HTML] Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults
B Killingley, AJ Mann, M Kalinova, A Boyers… - Nature Medicine, 2022 - nature.com
Since its emergence in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) has caused hundreds of millions of cases and continues to circulate globally. To establish …
2) has caused hundreds of millions of cases and continues to circulate globally. To establish …
Persistence and evolution of SARS-CoV-2 in an immunocompromised host
B Choi, MC Choudhary, J Regan… - … England Journal of …, 2020 - Mass Medical Soc
SARS-CoV-2 in an Immunocompromised Host This letter describes an
immunocompromised patient who had persistent infection with SARS-CoV-2 over a period …
immunocompromised patient who had persistent infection with SARS-CoV-2 over a period …
In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2
Remdesivir (RDV), a broadly acting nucleoside analogue, is the only FDA approved small
molecule antiviral for the treatment of COVID-19 patients. To date, there are no reports …
molecule antiviral for the treatment of COVID-19 patients. To date, there are no reports …
T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals
Long-term immunological memory to severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) is crucial for the development of population-level immunity, which is the aim …
(SARS-CoV-2) is crucial for the development of population-level immunity, which is the aim …
Dual antiviral therapy for persistent coronavirus disease 2019 and associated organizing pneumonia in an immunocompromised host
CA Trottier, B Wong, R Kohli… - Clinical Infectious …, 2023 - academic.oup.com
The management of patients with prolonged viral shedding and coronavirus disease 2019
symptoms remains unclear. Combining antivirals, as practiced in other infections, is …
symptoms remains unclear. Combining antivirals, as practiced in other infections, is …
SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses
LK Vibholm, SSF Nielsen, MH Pahus, GS Frattari… - …, 2021 - thelancet.com
Abstract Background Upon SARS-CoV-2 infection, most individuals develop neutralizing
antibodies and T-cell immunity. However, some individuals reportedly remain SARS-CoV-2 …
antibodies and T-cell immunity. However, some individuals reportedly remain SARS-CoV-2 …
Oral antiviral treatment for COVID-19: a comprehensive review on nirmatrelvir/ritonavir
Despite the rapid development of efficient and safe vaccines against COVID-19, the need to
confine the pandemic and treat infected individuals on an outpatient basis has led to the …
confine the pandemic and treat infected individuals on an outpatient basis has led to the …
The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient—A case study
C Sepulcri, C Dentone, M Mikulska… - Open forum …, 2021 - academic.oup.com
Background Immunocompromised patients show prolonged shedding of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) in nasopharyngeal swabs. We report a …
respiratory syndrome coronavirus 2 (SARS-CoV-2) in nasopharyngeal swabs. We report a …